SciFigSciFig
  • ๋„๊ตฌ

    ๋„๊ตฌ

    ๋ชจ๋“  SciFig ๊ทธ๋ฆผ ์ƒ์„ฑ๊ธฐ์™€ ๋ฒกํ„ฐ ์—๋””ํ„ฐ๋ฅผ ํ•œ๊ณณ์—์„œ.

    ๊ทธ๋ฆผ ๋„๊ตฌ

    ํ…์ŠคํŠธ์—์„œ ๊ทธ๋ฆผ

    ๋„ํ˜• ํ–ฅ์ƒ๊ธฐ

    ์Šค์ผ€์น˜์—์„œ ๊ทธ๋ฆผ

    ์ฐธ์กฐ์—์„œ ๊ทธ๋ฆผ

    PDF์—์„œ ๊ทธ๋ฆผ

    ์‚ฌ์ง„์—์„œ ๊ทธ๋ฆผ

    Vector Canvas

  • ๋ชจ๋ธ

    ๋ชจ๋ธ

    ์ €๋„ ๋…ผ๋ฌธ์—๋Š” GPT Image 2๋ฅผ ๊ธฐ๋ณธ์œผ๋กœ, ์Šฌ๋ผ์ด๋“œ์™€ ํฌ์Šคํ„ฐ์—๋Š” Nano Banana Pro๋ฅผ, ์ผ์ƒ์ ์ธ ๋„ํ˜• ์ž‘์—…์—๋Š” Nano Banana 2๋ฅผ ์‚ฌ์šฉํ•˜์„ธ์š”.

    ์—ฌ๊ธฐ์—์„œ ์‹œ์ž‘

    ๋ชจ๋ธ ๊ฐœ์š”

    ์ €๋„ ๋…ผ๋ฌธ์—๋Š” GPT Image 2๋ฅผ ๊ธฐ๋ณธ์œผ๋กœ ์‚ฌ์šฉํ•˜๊ณ , ์Šฌ๋ผ์ด๋“œ์™€ ํฌ์Šคํ„ฐ์—๋Š” Nano Banana Pro๋กœ ์ „ํ™˜ํ•˜๋ฉฐ, ์ผ์ƒ์ ์ธ ๋„ํ˜• ์ž‘์—…์—๋Š” Nano Banana 2๋ฅผ ์„ ํƒํ•˜์„ธ์š”

    ๋ชจ๋ธ ํŽ˜์ด์ง€

    GPT Image 2

    ์ถ”์ฒœ ๊ธฐ๋ณธ๊ฐ’ โ€” ์ €๋„ ํˆฌ๊ณ ์— ์ตœ์ : ํ™”ํ•™, ์ˆ˜์‹, ๋นฝ๋นฝํ•œ ๋ผ๋ฒจ์— ๊ฐ•ํ•ฉ๋‹ˆ๋‹ค

    Nano Banana Pro

    ํŽธ์ง‘ํ˜• ์Šคํƒ€์ผ ์ „๋ฌธ๊ฐ€ โ€” ์Šฌ๋ผ์ด๋“œ, ํฌ์Šคํ„ฐ, BioRender ์Šคํƒ€์ผ ๋„ํ˜•์— ์ตœ์ 

    Nano Banana 2

    ๊ท ํ˜• ์žกํžŒ ์ผ์ƒ์šฉ ๋ชจ๋ธ โ€” ์ผ์ƒ์ ์ธ ๊ทธ๋ฆผ ์ž‘์—…์„ ์œ„ํ•œ ์‹ค์šฉ์ ์ธ ์†๋„-ํ’ˆ์งˆ ๊ท ํ˜•

  • ์˜๊ฐ
  • ์‚ฌ์šฉ ๊ฐ€์ด๋“œ
  • ๋ธ”๋กœ๊ทธ
  • ์š”๊ธˆ์ œ
ํฌ๋ ˆ๋”ง ๋ณด์ƒ
ํ•œ๊ตญ์–ด
๋ฌด๋ฃŒ๋กœ ์‹œ์ž‘ํ•˜๊ธฐ
ํฌ๋ ˆ๋”ง ๋ณด์ƒ
ํ•œ๊ตญ์–ด
๋ฌด๋ฃŒ๋กœ ์‹œ์ž‘ํ•˜๊ธฐ
  1. ํ™ˆ
  2. /
  3. ๋ธ”๋กœ๊ทธ
  4. /
  5. ํŠœํ† ๋ฆฌ์–ผ
  6. /
  7. EHA 2026 ์—ฐ๊ตฌ์ž๋ฅผ ์œ„ํ•œ ์กฐํ˜ˆ ๋‹ค์ด์–ด๊ทธ๋žจ
ํŠœํ† ๋ฆฌ์–ผยท2026-05-22ยท32 min read

EHA 2026 ์—ฐ๊ตฌ์ž๋ฅผ ์œ„ํ•œ ์กฐํ˜ˆ ๋‹ค์ด์–ด๊ทธ๋žจ

EHA 2026 ํฌ์Šคํ„ฐ์šฉ ์ถœํŒ ์ค€๋น„ ์กฐํ˜ˆ ๋‹ค์ด์–ด๊ทธ๋žจ ์ž‘์„ฑ: ์ •๊ทœ ํŠธ๋ฆฌ, ๊ณจ์ˆ˜ niche, JAK/STAT ๊ฒฝ๋กœ, AML ์ฐจ๋‹จ, ๊ทธ๋ฆฌ๊ณ  AI ํ”„๋กฌํ”„ํŠธ.

SciFig Team

SciFig Team

Scientific Illustration Experts

์ด ํŽ˜์ด์ง€์—์„œ

  • 1. ์กฐํ˜ˆ ๋‹ค์ด์–ด๊ทธ๋žจ์ด ๊ฑฐ์˜ ๋ชจ๋“  EHA ํฌ์Šคํ„ฐ๋ฅผ ๋‹ป ๋‚ด๋ฆฌ๋Š” ์ด์œ 
  • 2. ์ •๊ทœ ์กฐํ˜ˆ ํŠธ๋ฆฌ: HSC์—์„œ 11๊ฐ€์ง€ ์„ฑ์ˆ™ ๊ณ„ํ†ต๊นŒ์ง€
  • 3. Myeloid vs Lymphoid: ์ฒซ ๋ฒˆ์งธ ์ฃผ์š” ๋ถ„๊ธฐ์ 
  • 4. ํ•ต์‹ฌ ์ค‘๊ฐ„ progenitor: CMP, GMP, MEP, CLP
  • 5. ๊ณจ์ˆ˜ ๋ฏธ์„ธํ™˜๊ฒฝ: ์ค„๊ธฐ์„ธํฌ ํฌ์Šคํ„ฐ๋ฅผ ์œ„ํ•œ niche ํ•ด๋ถ€
  • 6. ์กฐํ˜ˆ์„ ํ†ต์ œํ•˜๋Š” ์‹ ํ˜ธ ๊ฒฝ๋กœ: JAK/STAT, Wnt, Notch, SCF-c-Kit
  • 7. ์งˆ๋ณ‘์—์„œ์˜ ์กฐํ˜ˆ ๋ถ•๊ดด: AML, MDS, MPN, ๊ณจ์ˆ˜ ๋ถ€์ „
  • 8. AI ๊ธฐ๋ฐ˜ ์กฐํ˜ˆ ๋‹ค์ด์–ด๊ทธ๋žจ: ์ค„๊ธฐ์„ธํฌ ํฌ์Šคํ„ฐ๋ฅผ ์œ„ํ•œ SciFig ์›Œํฌํ”Œ๋กœ
  • 9. ๋ฌด๋ฃŒ ์ฒดํ—˜ CTA + ๊ด€๋ จ ์ฝ๊ธฐ ์ž๋ฃŒ: 5๊ฐ€์ง€ ๋ณต์‚ฌ-๋ถ™์—ฌ๋„ฃ๊ธฐ ์กฐํ˜ˆ ํ”„๋กฌํ”„ํŠธ
  • FAQ

์ƒ๋‹จ์˜ ์กฐํ˜ˆ ์ค„๊ธฐ์„ธํฌ์—์„œ ์‹œ์ž‘ํ•ด multipotent progenitor๋ฅผ ๊ฑฐ์ณ ์•„๋ž˜๋กœ ๋ถ„๊ธฐ์‹œํ‚ค๊ณ , myeloid์™€ lymphoid ๋ถ„๊ธฐ๋กœ ๋‚˜๋‰œ ๋‹ค์Œ, granulocyte-monocyte progenitor ๊ทผ์ฒ˜ ์–ด๋””์ฏค์—์„œ ๋„ํ˜•์ด ์ƒ๋ฌผํ•™์ ์œผ๋กœ ๋ง์ด ๋˜์ง€ ์•Š๊ฒŒ ๋ฉ๋‹ˆ๋‹ค. GPT image๋Š” megakaryocyte๊ฐ€ CLP์—์„œ ๋ถ„๊ธฐ๋˜์–ด ๋‚˜์˜ค๊ฒŒ ๊ทธ๋ ค์•ผ ํ•œ๋‹ค๊ณ  ์šฐ๊น๋‹ˆ๋‹ค. Midjourney๋Š” myeloid-lymphoid ๋ถ„๊ธฐ๋ฅผ ๋’ค์ง‘์Šต๋‹ˆ๋‹ค. "CD34+ E-progenitor"๋ผ๋Š” ๋ฐ์€ ๋ผ๋ฒจ์ด ๋‚˜ํƒ€๋‚ฉ๋‹ˆ๋‹ค โ€” ์กด์žฌํ•˜์ง€ ์•Š๋Š” ์„ธํฌ ์œ ํ˜•์ž…๋‹ˆ๋‹ค. ๋‹ค์‹œ ๊ตด๋ฆฌ๋ฉด ๋‹ค์Œ ๋ฒ„์ „์€ erythrocyte๋ฅผ lymphoid ๊ณ„ํ†ต ์•„๋ž˜์— ๋†“์Šต๋‹ˆ๋‹ค. 40๋ถ„ ํ›„ ํฌ๊ธฐํ•˜๊ณ  Illustrator์—์„œ ๊ต๊ณผ์„œ ํŠธ๋ฆฌ๋ฅผ ์†์œผ๋กœ ๋”ฐ๋ผ ๊ทธ๋ฆฝ๋‹ˆ๋‹ค.

์ด๋Š” EHA์—์„œ ๋Œ€๋ถ€๋ถ„์˜ ์ค„๊ธฐ์„ธํฌ ๋ฐ ํ˜ˆ์•กํ•™์  ์•…์„ฑ์ข…์–‘ ํฌ์Šคํ„ฐ๋ฅผ ํƒˆ์„ ์‹œํ‚ค๋Š” ์ˆœ๊ฐ„์ž…๋‹ˆ๋‹ค. ์กฐํ˜ˆ ํŠธ๋ฆฌ๋Š” ํ˜ˆ์•กํ•™์—์„œ ๊ฐ€์žฅ ๊ธฐ์ดˆ์ ์ธ ๋„ํ˜• โ€” ๋ชจ๋“  ์‹ฌ์‚ฌ์œ„์›์ด ๋‹น์‹ ์˜ ๊ณผํ•™์„ ๋‹ค๋ฃจ๊ธฐ ์ „์— ๊ธฐ๋Œ€ํ•˜๋Š” ๋ฐฉํ–ฅ ์ง€๋„ โ€” ์ด๋ฉฐ ํ† ํด๋กœ์ง€๊ฐ€ ์šฉ์„œ๊ฐ€ ์—†๊ธฐ ๋•Œ๋ฌธ์— ์ผ๋ฐ˜ AI ์ด๋ฏธ์ง€ ๋ชจ๋ธ์ด ๊ฐ€์žฅ ์ผ๊ด€๋˜๊ฒŒ ์‹คํŒจํ•˜๋Š” ๋‹จ์ผ ๋„ํ˜•์ž…๋‹ˆ๋‹ค. ํ•˜๋‚˜์˜ ๋ถ„๊ธฐ๊ฐ€ ๋’ค์ง‘ํžˆ๋ฉด ์ „์ฒด ๊ณ„ํ†ต ์ถ”๋ก ์ด ๋ฌด๋„ˆ์ง‘๋‹ˆ๋‹ค. ์ด ๊ฐ€์ด๋“œ๋Š” HSC์—์„œ 11๊ฐœ์˜ ์„ฑ์ˆ™ ๊ณ„ํ†ต๊นŒ์ง€์˜ ์ •๊ทœ ์กฐํ˜ˆ ํŠธ๋ฆฌ, ๊ณจ์ˆ˜ niche ์•„ํ‚คํ…์ฒ˜, ์ž๊ธฐ ์žฌ์ƒ ๋Œ€ ๋ถ„ํ™”๋ฅผ ํ†ต์ œํ•˜๋Š” ์‹ ํ˜ธ ๊ฒฝ๋กœ, ์กฐํ˜ˆ์ด ๋ฌด๋„ˆ์ง€๋Š” ์งˆํ™˜ ์ƒํƒœ, ๊ทธ๋ฆฌ๊ณ  ์ฒซ ์ดˆ์•ˆ์—์„œ ํ† ํด๋กœ์ง€๋ฅผ ์˜ฌ๋ฐ”๋ฅด๊ฒŒ ๋งŒ๋“œ๋Š” AI ๋ณด์กฐ ์›Œํฌํ”Œ๋กœ๋ฅผ ๋‹ค๋ฃน๋‹ˆ๋‹ค.

์กฐํ˜ˆ ํŠธ๋ฆฌ: HSC โ†’ MPP โ†’ CMP (myeloid) ๋ฐ CLP (lymphoid) ๊ณ„ํ†ต โ†’ 11๊ฐ€์ง€ ์„ฑ์ˆ™ ํ˜ˆ์•ก ์„ธํฌ ์œ ํ˜• (SciFig์œผ๋กœ ์ƒ์„ฑ๋œ ๊ทธ๋ฆผ)
์กฐํ˜ˆ ํŠธ๋ฆฌ: HSC โ†’ MPP โ†’ CMP (myeloid) ๋ฐ CLP (lymphoid) ๊ณ„ํ†ต โ†’ 11๊ฐ€์ง€ ์„ฑ์ˆ™ ํ˜ˆ์•ก ์„ธํฌ ์œ ํ˜• (SciFig์œผ๋กœ ์ƒ์„ฑ๋œ ๊ทธ๋ฆผ)

ํˆฌ๋ช…์„ฑ ์•ˆ๋‚ด: ๋ณธ ๊ธ€์˜ ์ผ๋Ÿฌ์ŠคํŠธ๋Š” SciFig AI๋กœ ์ƒ์„ฑ๋˜์—ˆ์œผ๋ฉฐ, ๊ณผํ•™์  ์ •ํ™•์„ฑ์— ๋Œ€ํ•ด ์ €์ž๊ฐ€ ๊ฒ€ํ† ํ–ˆ์Šต๋‹ˆ๋‹ค. ์ธ์šฉ๋œ ์ฃผ์žฅ์€ ๋™๋ฃŒ ์‹ฌ์‚ฌ ์ž๋ฃŒ, NIH ๊ต์œก ์ž๋ฃŒ, ASH Education Book์œผ๋กœ ์—ฐ๊ฒฐ๋ฉ๋‹ˆ๋‹ค.

1. ์กฐํ˜ˆ ๋‹ค์ด์–ด๊ทธ๋žจ์ด ๊ฑฐ์˜ ๋ชจ๋“  EHA ํฌ์Šคํ„ฐ๋ฅผ ๋‹ป ๋‚ด๋ฆฌ๋Š” ์ด์œ 

์–ด๋–ค EHA ํฌ์Šคํ„ฐ ์„ธ์…˜์„ ๊ฑธ์–ด๋„ ๊ฑฐ์˜ ๋ชจ๋“  ์ค„๊ธฐ์„ธํฌ, ๋ฐฑํ˜ˆ๋ณ‘, ๋ฆผํ”„์ข…, ๊ณจ์ˆ˜์ข…, ์ด์‹ ํฌ์Šคํ„ฐ์˜ ๋„์ž… ํŒจ๋„์—์„œ ๋‹จ์ˆœํ™”๋œ ์กฐํ˜ˆ ํŠธ๋ฆฌ๋ฅผ ๋ณผ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ์ด์œ ๋Š” ๊ฐœ๋…์ ์ž…๋‹ˆ๋‹ค. ํ˜ˆ์•กํ•™์€ ๊ฐ ์„ธํฌ ์œ ํ˜•์ด ์–ด๋””์„œ ์™”๋Š”์ง€์— ๋Œ€ํ•œ ๊ณต์œ ๋œ ์ •์‹  ๋ชจ๋ธ ์œ„์—์„œ ์ž‘๋™ํ•˜๋ฉฐ, ๋‹น์‹ ์˜ ์—ฐ๊ตฌ๋Š” ์•”๋ฌต์ ์œผ๋กœ ๊ทธ ๊ณ„ํ†ต์˜ ์–ด๋А ์ง€์ ์—์„œ ์ค‘์žฌํ•˜๋Š”์ง€์— ๋Œ€ํ•œ ์ฃผ์žฅ์ž…๋‹ˆ๋‹ค. ํŠธ๋ฆฌ๋ฅผ ๋ช…ํ™•ํ•˜๊ฒŒ ๋ณด์—ฌ์ค„ ์ˆ˜ ์—†๋‹ค๋ฉด ์—ฐ๊ตฌ๋ฅผ ๋ช…ํ™•ํ•˜๊ฒŒ ๋ณด์—ฌ์ค„ ์ˆ˜ ์—†์Šต๋‹ˆ๋‹ค.

EHA 2026 ํ”„๋กœ๊ทธ๋žจ์€ Hematopoiesis, stem cells and microenvironment๋ฅผ Tier 2 ์ดˆ๋ก ์ฃผ์ œ๋กœ ๋ถ„๋ฅ˜ํ•ฉ๋‹ˆ๋‹ค โ€” 6์›” 11์ผ์— ์ค„๊ธฐ์„ธํฌ ์ƒ๋ฌผํ•™, ํ˜ˆ์•กํ•™์  ์•…์„ฑ์ข…์–‘, ์‹ ํ˜ธ์ „๋‹ฌ, ๋ฐœ๋‹ฌ ์กฐํ˜ˆ, ์—ผ์ฆ, epigenome, ๋…ธํ™”, ํด๋ก  ์กฐํ˜ˆ, ์œ ์ „์ž ์น˜๋ฃŒ, ๋Œ€์‚ฌ, ๋ฏธ์„ธํ™˜๊ฒฝ, ์‹ ๊ธฐ์ˆ ์„ ๋‹ค๋ฃฐ ์—ฐ๋ก€ Molecular Hematopoiesis Workshop์„ ํฌ๊ด„ํ•  ๋งŒํผ ๊ด‘๋ฒ”์œ„ํ•ฉ๋‹ˆ๋‹ค. ๊ทธ ๋ชจ๋“  ํ•˜์œ„ ์ฃผ์ œ๋Š” ์กฐํ˜ˆ ๋งฅ๋ฝ ๋„ํ˜•์ด ํ•„์š”ํ•ฉ๋‹ˆ๋‹ค. ์ด ๊ฐ€์ด๋“œ๋Š” ๊ฐ€์žฅ ๋ณดํŽธ์ ์ธ 6๊ฐ€์ง€๋ฅผ ๋‹ค๋ฃน๋‹ˆ๋‹ค.

2. ์ •๊ทœ ์กฐํ˜ˆ ํŠธ๋ฆฌ: HSC์—์„œ 11๊ฐ€์ง€ ์„ฑ์ˆ™ ๊ณ„ํ†ต๊นŒ์ง€

์ •๊ทœ ์กฐํ˜ˆ ํŠธ๋ฆฌ๋Š” ์กฐํ˜ˆ ์ค„๊ธฐ์„ธํฌ(HSC)์—์„œ ์‹œ์ž‘ํ•ฉ๋‹ˆ๋‹ค โ€” ๊ณจ์ˆ˜ niche์— ์กฐ์šฉํžˆ ์ž๋ฆฌ ์žก์€ ์žฅ๊ธฐ ์ž๊ธฐ ์žฌ์ƒ ์„ธํฌ. HSC๋Š” multipotent progenitor(MPP)๋ฅผ ๋‚ณ์œผ๋ฉฐ, MPP๋Š” ์ž๊ธฐ ์žฌ์ƒ ๋Šฅ๋ ฅ์„ ์žƒ์ง€๋งŒ ๊ด‘๋ฒ”์œ„ํ•œ ๊ณ„ํ†ต ์ž ์žฌ๋ ฅ์„ ์œ ์ง€ํ•ฉ๋‹ˆ๋‹ค. MPP์—์„œ ํŠธ๋ฆฌ๊ฐ€ ๋ถ„๊ธฐ๋ฉ๋‹ˆ๋‹ค. common myeloid progenitor(CMP)๋Š” ๋ชจ๋“  myeloid ๊ณ„ํ†ต์„ ๋‚ณ๊ณ , common lymphoid progenitor(CLP)๋Š” ๋ชจ๋“  lymphoid ๊ณ„ํ†ต์„ ๋‚ณ์Šต๋‹ˆ๋‹ค. ๊ด€๋ก€์ƒ 11๊ฐ€์ง€ ์„ฑ์ˆ™ ๊ณ„ํ†ต์€ ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค. erythrocyte, megakaryocyte(plasma), neutrophil, eosinophil, basophil, monocyte/macrophage, dendritic cell, mast cell, NK cell, B cell, T cell.

์ด๊ฒƒ์ด ํ† ํด๋กœ์ง€์ด์ง€๋งŒ, ์‹ค์ œ ๋„ํ˜•์€ ์šฉ์„œ๊ฐ€ ์—†์Šต๋‹ˆ๋‹ค. Myeloid ๋ถ„๊ธฐ๋Š” megakaryocyte-erythroid progenitor(MEP)๋ฅผ ํ†ตํ•ด erythrocyte์™€ megakaryocyte๋ฅผ ๋‚ณ์•„์•ผ ํ•ฉ๋‹ˆ๋‹ค. Lymphoid ๋ถ„๊ธฐ๋Š” ๊ทธ๋ž˜์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค. Mast cell๊ณผ dendritic cell์€ ๋Œ€๋ถ€๋ถ„์˜ ๋„ํ˜•์ด ๋‹จ์ˆœํ™”ํ•˜๋Š” ๋ณต์žกํ•œ ์ด์ค‘ ๊ธฐ์›์„ ๊ฐ€์ง‘๋‹ˆ๋‹ค. ๊ถŒ์œ„ ์žˆ๋Š” ์ฐธ์กฐ ์ง€์ : NIH ์กฐํ˜ˆ ์‚ฌ์ „ ํ•ญ๋ชฉ๊ณผ ASH ์กฐํ˜ˆ ๊ต์œก ์ถœํŒ ํฌํ„ธ์ด ๋„ํ˜•์„ ๋Œ€์กฐํ•  ์ˆ˜ ์žˆ๋Š” ์ผ๊ด€๋œ ํ† ํด๋กœ์ง€๋ฅผ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค.

์‹œ๊ฐ์  ๋ฆฌํ„ฐ๋Ÿฌ์‹œ ๊ธฐ์ค€์ด ๋†’์Šต๋‹ˆ๋‹ค. ํ™€์˜ ๋ชจ๋“  ์‹ฌ์‚ฌ์œ„์›์ด ์ด ํŠธ๋ฆฌ๋ฅผ ์ˆ˜์ฒœ ๋ฒˆ ๋ดค๊ธฐ ๋•Œ๋ฌธ์ž…๋‹ˆ๋‹ค. ๋‹น์‹ ์˜ ๊ฒƒ์€ ์ถœํŒ ๋“ฑ๊ธ‰ ๋ช…๋ฃŒ์„ฑ์œผ๋กœ ์ •๊ทœ ํ† ํด๋กœ์ง€๋ฅผ ์ผ์น˜์‹œํ‚ค๊ฑฐ๋‚˜ โ€” ๋˜๋Š” ์—ฐ๊ตฌ๊ฐ€ ํŠน์ • ๊ณ„ํ†ต ๊ฒฐ์ • ์ง€์ ์„ ๋‹ค๋ฃฌ๋‹ค๋ฉด โ€” ์ค‘์žฌ๊ฐ€ ํŠธ๋ฆฌ์˜ ์–ด๋””์— ์žˆ๋Š”์ง€ ์ •ํ™•ํžˆ ๊ฐ•์กฐํ•˜๋„๋ก ์ฃผ์„์„ ๋‹ฌ์•„์•ผ ํ•ฉ๋‹ˆ๋‹ค.

3. Myeloid vs Lymphoid: ์ฒซ ๋ฒˆ์งธ ์ฃผ์š” ๋ถ„๊ธฐ์ 

MPP์—์„œ์˜ CMP-CLP ๋ถ„๊ธฐ๋Š” ์กฐํ˜ˆ์—์„œ ๊ฐ€์žฅ ๊ฒฐ์ •์ ์ธ ๋ถ„๊ธฐ ๊ฒฐ์ •์ด๋ฉฐ, ์ผ๋ฐ˜ AI ์ด๋ฏธ์ง€ ๋ชจ๋ธ์ด ํ† ํด๋กœ์ง€๋ฅผ ๊ฐ€์žฅ ์ž์ฃผ ๋’ค์ง‘๋Š” ๊ณณ์ด๊ธฐ๋„ ํ•ฉ๋‹ˆ๋‹ค. ์ด๊ฒƒ์„ ์ž˜๋ชป ๋งŒ๋“ค๋ฉด ๋ชจ๋“  ํ•˜๋ฅ˜ ๊ณ„ํ†ต์ด ์ž˜๋ชป ๋ผ๋ฒจ๋ฉ๋‹ˆ๋‹ค.

๋ถ„๊ธฐ๋Š” ๊ฒฝ์Ÿํ•˜๋Š” ์ „์‚ฌ ์ธ์ž์— ์˜ํ•ด ์กฐ์ ˆ๋ฉ๋‹ˆ๋‹ค โ€” PU.1์€ myeloid ์ปค๋ฐ‹๋จผํŠธ๋ฅผ ์„ ํ˜ธํ•˜๊ณ , Ikaros์™€ E2A๋Š” lymphoid ์ปค๋ฐ‹๋จผํŠธ๋ฅผ ์„ ํ˜ธํ•ฉ๋‹ˆ๋‹ค. ๋‘ ๋”ธ ์ง‘๋‹จ์€ ๊ทผ๋ณธ์ ์œผ๋กœ ๋‹ค๋ฅธ ํ•˜๋ฅ˜ ์šด๋ช…์„ ๊ฐ€์ง‘๋‹ˆ๋‹ค. CMP๋Š” ์ ํ˜ˆ๊ตฌ, ํ˜ˆ์†ŒํŒ, granulocyte, monocyte, mast cell, ๋Œ€๋ถ€๋ถ„์˜ dendritic cell์„ ๋‚ณ์Šต๋‹ˆ๋‹ค. CLP๋Š” T cell, B cell, NK cell, plasmacytoid dendritic cell์„ ๋‚ณ์Šต๋‹ˆ๋‹ค. ์ด๋ฅผ ์„ž์€ ๋„ํ˜•์€ ์–‘์‹์  ์„ ํƒ์ด ์•„๋‹™๋‹ˆ๋‹ค. ๊ฒฝํ—˜ ๋งŽ์€ ์‹ฌ์‚ฌ์œ„์›์ด ์ œ๋ชฉ์„ ์ฝ๊ธฐ ์ „์— ๋ฐœ๊ฒฌํ•˜๋Š” ํ† ํด๋กœ์ง€ ์˜ค๋ฅ˜์ž…๋‹ˆ๋‹ค.

๊ธ‰์„ฑ ๊ณจ์ˆ˜์„ฑ ๋ฐฑํ˜ˆ๋ณ‘์„ ๋‹ค๋ฃจ๋Š” ํฌ์Šคํ„ฐ์˜ ๊ฒฝ์šฐ, myeloid ๋ถ„๊ธฐ๋Š” ์ค‘๊ฐ„ progenitor์™€ ํ•จ๊ป˜ ํ™•์žฅ๋˜์–ด์•ผ ํ•ฉ๋‹ˆ๋‹ค(CMP โ†’ GMP โ†’ myeloblast โ†’ granulocyte/monocyte). T ์„ธํฌ ๋˜๋Š” B ์„ธํฌ ์•…์„ฑ์ข…์–‘์„ ๋‹ค๋ฃจ๋Š” ํฌ์Šคํ„ฐ์˜ ๊ฒฝ์šฐ, lymphoid ๋ถ„๊ธฐ๋Š” ํ‰์„  ๋ฐ ๊ณจ์ˆ˜ lymphoid ๊ถค์ ์„ ๋ณ„๋„๋กœ ๊ทธ๋ ค์•ผ ํ•ฉ๋‹ˆ๋‹ค.

4. ํ•ต์‹ฌ ์ค‘๊ฐ„ progenitor: CMP, GMP, MEP, CLP

MPP ์•„๋ž˜์—์„œ ๊ฐ€์žฅ ์ค‘์š”ํ•œ ๋„ค ๊ฐ€์ง€ ์ค‘๊ฐ„ progenitor๋Š” CMP, GMP, MEP, CLP์ž…๋‹ˆ๋‹ค. ์ด๋“ค์€ ์กฐํ˜ˆ์˜ "๋ช…๋ช…๋œ ๊ฒŒ์ดํŠธ"์ž…๋‹ˆ๋‹ค โ€” ๊ฐ๊ฐ์€ ํŠน์ • ํ‘œ๋ฉด ๋งˆ์ปค ์กฐํ•ฉ(๊ฐ€์žฅ ํ”ํžˆ CD34, CD38, CD45RA, CD123, CD135/Flt3)๊ณผ ํ•˜๋ฅ˜ ๊ณ„ํ†ต ์ž ์žฌ๋ ฅ์œผ๋กœ ์ •์˜๋ฉ๋‹ˆ๋‹ค.

  • CMP (common myeloid progenitor) โ€” CD34+CD38+CD123+CD45RAโˆ’. GMP์™€ MEP๋ฅผ ๋‚ณ์Œ.
  • GMP (granulocyte-monocyte progenitor) โ€” CD34+CD38+CD123+CD45RA+. Neutrophil, eosinophil, basophil, monocyte, mast cell, ํ†ต์ƒ์ ์ธ dendritic cell์„ ๋‚ณ์Œ.
  • MEP (megakaryocyte-erythroid progenitor) โ€” CD34+CD38+CD123lowCD45RAโˆ’. Erythrocyte์™€ megakaryocyte/ํ˜ˆ์†ŒํŒ์„ ๋‚ณ์Œ.
  • CLP (common lymphoid progenitor) โ€” CD34+CD38+CD7+CD10+CD45RA+. T cell, B cell, NK cell, plasmacytoid dendritic cell์„ ๋‚ณ์Œ.

์ •ํ™•ํ•œ ๋„ํ˜•์€ ๊ฐ ์ค‘๊ฐ„ ๋‹จ๊ณ„์— ํ‘œ๋ฉด ๋งˆ์ปค ํ‘œํ˜„ํ˜•๊ณผ ํ•˜๋ฅ˜ ๊ณ„ํ†ต์„ ์ฃผ์„์œผ๋กœ ๋‹ต๋‹ˆ๋‹ค. ๋ถ€์ •ํ™•ํ•œ ๋„ํ˜• โ€” ๊ทธ๋ฆฌ๊ณ  ๋งŽ์€ AI ์ƒ์„ฑ ์ดˆ์•ˆ โ€” ์€ ์กด์žฌํ•˜์ง€ ์•Š๋Š” ์ค‘๊ฐ„ ์ด๋ฆ„(์˜ˆ: "CD34+ E-progenitor" ๋˜๋Š” "early myeloid blast")์„ ๋ฐœ๋ช…ํ•ด ์‹ฌ์‚ฌ์œ„์›์—๊ฒŒ ์ •๊ทœ ๋ถ„๋ฅ˜ํ•™์„ ๋ชจ๋ฅธ๋‹ค๋Š” ์‹ ํ˜ธ๋ฅผ ๋ณด๋ƒ…๋‹ˆ๋‹ค.

5. ๊ณจ์ˆ˜ ๋ฏธ์„ธํ™˜๊ฒฝ: ์ค„๊ธฐ์„ธํฌ ํฌ์Šคํ„ฐ๋ฅผ ์œ„ํ•œ niche ํ•ด๋ถ€

๊ณจ์ˆ˜ niche๋Š” HSC๊ฐ€ ์‚ด๊ณ , ๋ถ„์—ดํ•˜๊ณ , ์ž๊ธฐ ์žฌ์ƒ๊ณผ ๋ถ„ํ™” ์ค‘ ์–ด๋А ์ชฝ์„ ํ• ์ง€ ๊ฒฐ์ •ํ•˜๋Š” ๋ฌผ๋ฆฌ์  ๋ฐ ๋ถ„์ž์  ํ™˜๊ฒฝ์ž…๋‹ˆ๋‹ค. ์ •๊ทœ ์ฐธ์กฐ๋Š” Morrison๊ณผ Scadden 2014 Nature ๋ฆฌ๋ทฐ: ์กฐํ˜ˆ ์ค„๊ธฐ์„ธํฌ๋ฅผ ์œ„ํ•œ ๊ณจ์ˆ˜ niche์ด๋ฉฐ, ์ค‘์ฒฉ๋œ ํ˜ˆ๊ด€, ํ˜ˆ๊ด€์ฃผ๋ณ€, ๊ณจ๋ชจ์„ธํฌ ๊ตฌํš์˜ ํ˜„๋Œ€ ๋ชจ๋ธ์„ ๊ณต์‹ํ™”ํ–ˆ์Šต๋‹ˆ๋‹ค.

๋„ํ˜•์ด ๊ตฌ๋ถ„ํ•ด์•ผ ํ•  ์„ธ ๊ฐ€์ง€ niche ๊ตฌํš:

  • ํ˜ˆ๊ด€ niche โ€” Sinusoidal endothelium ๊ทผ์ฒ˜. ํ™œ์„ฑ ์ฃผ๊ธฐ์— ์žˆ๋Š” HSC์— ์‚ฐ์†Œ์™€ ์‹ ํ˜ธ ์‹ ํ˜ธ๋ฅผ ์ œ๊ณต.
  • ํ˜ˆ๊ด€์ฃผ๋ณ€ niche โ€” ํ˜ˆ๊ด€ ์ฃผ๋ณ€์˜ mesenchymal stromal cell(MSC)๊ณผ CXCL12-abundant reticular(CAR) cell. HSC๋ฅผ ๊ณ ์ •์‹œํ‚ค๋Š” CXCL12(SDF-1)์˜ ์ฃผ์š” ๊ณต๊ธ‰์›.
  • ๊ณจ๋ชจ์„ธํฌ niche โ€” ๋ผˆ ํ‘œ๋ฉด ๊ทผ์ฒ˜. ์—ญ์‚ฌ์ ์œผ๋กœ HSC ์ •์ง€์™€ ์—ฐ๊ด€, ํ˜„๋Œ€ ๋ชจ๋ธ์€ ์˜ค๋ž˜๋œ "๊ณจ๋‚ด๋ง‰" ๊ฒฌํ•ด๋ณด๋‹ค ํ˜ˆ๊ด€/ํ˜ˆ๊ด€์ฃผ๋ณ€์„ ๋” ๊ฐ•์กฐ.
๊ณจ์ˆ˜ niche: sinusoidal ํ˜ˆ๊ด€, ํ˜ˆ๊ด€์ฃผ๋ณ€ MSC์™€ CAR cell, ๊ณจ๋ชจ์„ธํฌ ํ‘œ๋ฉด, ๊ต๊ฐ ์‹ ๊ฒฝ (SciFig์œผ๋กœ ์ƒ์„ฑ๋œ ๊ทธ๋ฆผ)
๊ณจ์ˆ˜ niche: sinusoidal ํ˜ˆ๊ด€, ํ˜ˆ๊ด€์ฃผ๋ณ€ MSC์™€ CAR cell, ๊ณจ๋ชจ์„ธํฌ ํ‘œ๋ฉด, ๊ต๊ฐ ์‹ ๊ฒฝ (SciFig์œผ๋กœ ์ƒ์„ฑ๋œ ๊ทธ๋ฆผ)

๊ต๊ฐ ์‹ ๊ฒฝ ์„ฌ์œ ๋Š” ํ˜ˆ๋ฅ˜๋กœ์˜ ์ผ์ฃผ๊ธฐ HSC ์ดํƒˆ์„ ํ†ต์ œํ•จ์œผ๋กœ์จ ๋„ค ๋ฒˆ์งธ ์กฐ์ ˆ ์ธต์„ ์ถ”๊ฐ€ํ•ฉ๋‹ˆ๋‹ค. ๋™์›(G-CSF, plerixafor) ๋˜๋Š” ํŠธ๋ž˜ํ”ฝํ‚น์„ ๋‹ค๋ฃจ๋Š” ํฌ์Šคํ„ฐ์˜ ๊ฒฝ์šฐ ์ด๋ฅผ ๋ณด์—ฌ์ฃผ๋Š” ๊ฒƒ์ด ํ•„์ˆ˜์ž…๋‹ˆ๋‹ค. AML ๋˜๋Š” MDS๋ฅผ ๋‹ค๋ฃจ๋Š” ํฌ์Šคํ„ฐ์˜ ๊ฒฝ์šฐ, niche ๋„ํ˜•์€ leukemic stem cell ๊ด€์ ๋„ ํฌํ•จํ•ด์•ผ ํ•ฉ๋‹ˆ๋‹ค โ€” ์•…์„ฑ HSC๊ฐ€ niche๋ฅผ ์–ด๋–ป๊ฒŒ ์ ์œ ํ•˜๊ณ  ์ •์ƒ HSC๋ฅผ ๋Šฅ๊ฐ€ํ•˜๋Š”์ง€.

6. ์กฐํ˜ˆ์„ ํ†ต์ œํ•˜๋Š” ์‹ ํ˜ธ ๊ฒฝ๋กœ: JAK/STAT, Wnt, Notch, SCF-c-Kit

๋„ค ๊ฐ€์ง€ ์‹ ํ˜ธ ๊ฒฝ๋กœ๊ฐ€ ์กฐํ˜ˆ ์กฐ์ ˆ์„ ์ง€๋ฐฐํ•˜๋ฉฐ, ๊ฐ๊ฐ์€ ์ •์ƒ ์กฐ์ ˆ์ž ๋˜๋Š” ์งˆํ™˜ ๋™์ธ์œผ๋กœ EHA ํฌ์Šคํ„ฐ์— ์ž์ฃผ ๋“ฑ์žฅํ•ฉ๋‹ˆ๋‹ค.

  • SCF-c-Kit โ€” Stem cell factor๊ฐ€ c-Kit ์ˆ˜์šฉ์ฒด(CD117)์— ๊ฒฐํ•ฉํ•ด HSC ์ƒ์กด๊ณผ ์ดˆ๊ธฐ ๊ณ„ํ†ต ๊ฒฐ์ •์„ ์œ ๋„. KIT ๋ณ€์ด๋Š” ์ „์‹ ์„ฑ mastocytosis์˜ ์ค‘์‹ฌ.
  • Thrombopoietin (TPO)-MPL โ†’ JAK/STAT โ€” TPO๊ฐ€ MPL์— ๊ฒฐํ•ฉํ•ด JAK2๋ฅผ ํ™œ์„ฑํ™”ํ•˜๊ณ , JAK2๊ฐ€ STAT3/STAT5๋ฅผ ์ธ์‚ฐํ™”. ์ธ์‚ฐํ™”๋œ STAT ์ดํ•ฉ์ฒด๊ฐ€ ํ•ต์œผ๋กœ ์ „์œ„ํ•ด ์ž๊ธฐ ์žฌ์ƒ ๋ฐ ์ƒ์กด ์œ ์ „์ž์˜ ์ „์‚ฌ๋ฅผ ํ™œ์„ฑํ™”. JAK2 V617F ๋ณ€์ด๊ฐ€ ๊ณจ์ˆ˜์ฆ์‹์ข…์–‘์„ ์œ ๋„.
  • Wnt/ฮฒ-catenin โ€” ์ •๊ทœ Wnt ์‹ ํ˜ธ๋Š” HSC ์ž๊ธฐ ์žฌ์ƒ์„ ์ง€์›. ๋น„์ •์ƒ ํ™œ์„ฑํ™”๋Š” ๋ฐฑํ˜ˆ๋ณ‘ ํ˜•์งˆ์ „ํ™˜์— ๊ธฐ์—ฌ.
  • Notch โ€” Notch-Delta ์ƒํ˜ธ์ž‘์šฉ์ด ํ‰์„ ์—์„œ T-cell ๊ณ„ํ†ต ์ปค๋ฐ‹๋จผํŠธ๋ฅผ ์œ ๋„. ๋น„์ •์ƒ Notch ์‹ ํ˜ธ๊ฐ€ T-ALL์„ ์œ ๋„.
HSC ์‹ ํ˜ธ: SCF-c-Kit, TPO/JAK-STAT, Wnt/ฮฒ-catenin, Notch โ€” ์ž๊ธฐ ์žฌ์ƒ vs ๋ถ„ํ™” ํ†ต์ œ (SciFig์œผ๋กœ ์ƒ์„ฑ๋œ ๊ทธ๋ฆผ)
HSC ์‹ ํ˜ธ: SCF-c-Kit, TPO/JAK-STAT, Wnt/ฮฒ-catenin, Notch โ€” ์ž๊ธฐ ์žฌ์ƒ vs ๋ถ„ํ™” ํ†ต์ œ (SciFig์œผ๋กœ ์ƒ์„ฑ๋œ ๊ทธ๋ฆผ)

JAK/STAT ์บ์Šค์ผ€์ด๋“œ๋Š” AI ์ด๋ฏธ์ง€ ๋ชจ๋ธ์ด ๊ฐ€์žฅ ์ž์ฃผ ์‹ ํ˜ธ ํ๋ฆ„ ๋ฐฉํ–ฅ์„ ๋’ค์ง‘๋Š” ๊ณณ์ž…๋‹ˆ๋‹ค. ์ •๊ทœ ์ˆœ์„œ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค. Cytokine์ด ์ˆ˜์šฉ์ฒด์— ๊ฒฐํ•ฉ โ†’ ์ˆ˜์šฉ์ฒด ๊ฒฐํ•ฉ JAK kinase๊ฐ€ trans-phosphorylate โ†’ JAK์ด STAT tyrosine ์ž”๊ธฐ๋ฅผ ์ธ์‚ฐํ™” โ†’ ์ธ์‚ฐํ™”๋œ STAT์ด SH2 ๋„๋ฉ”์ธ ์ƒํ˜ธ์ž‘์šฉ์„ ํ†ตํ•ด ์ดํ•ฉ์ฒดํ™” โ†’ ์ดํ•ฉ์ฒด๊ฐ€ ํ•ต์œผ๋กœ ์ „์œ„ โ†’ ์ „์‚ฌ. ์ผ๋ฐ˜ AI ์ƒ์„ฑ๊ธฐ๋Š” ์ž์ฃผ STAT์ด ๋จผ์ € ํ•ต์— ๋“ค์–ด๊ฐ€๊ณ  ๊ทธ ๋‹ค์Œ์— ์ดํ•ฉ์ฒดํ™”ํ•˜๋Š” ๊ฒƒ์œผ๋กœ ๊ทธ๋ฆฌ๋Š”๋ฐ, ์ด๋Š” ์ž˜๋ชป๋œ ์ˆœ์„œ์ž…๋‹ˆ๋‹ค โ€” ๋ถ„์ž์ƒ๋ฌผํ•™ ๊ฐ๋… ์—†์ด ๋„ํ˜•์ด ์ƒ์„ฑ๋˜์—ˆ๋‹ค๋Š” ์‹ฌ์‚ฌ์œ„์›์—๊ฒŒ ๋ณด๋‚ด๋Š” ๋ช…ํ™•ํ•œ ์‹ ํ˜ธ.

7. ์งˆ๋ณ‘์—์„œ์˜ ์กฐํ˜ˆ ๋ถ•๊ดด: AML, MDS, MPN, ๊ณจ์ˆ˜ ๋ถ€์ „

๋Œ€๋ถ€๋ถ„์˜ EHA ์งˆํ™˜ ์ค‘์‹ฌ ํฌ์Šคํ„ฐ๋Š” ํŠน์ • ์งˆํ™˜์—์„œ ์กฐํ˜ˆ์ด ์–ด๋””์„œ ๋ฌด๋„ˆ์ง€๋Š”์ง€ ๋ณด์—ฌ์ฃผ๋Š” ๋„ํ˜•์ด ํ•„์š”ํ•ฉ๋‹ˆ๋‹ค. ๋„ค ๊ฐ€์ง€ ๊ณ ๋นˆ๋„ ์˜ˆ์‹œ๊ฐ€ ํ”„๋กœ๊ทธ๋žจ์˜ ๋Œ€๋ถ€๋ถ„์„ ๋‹ค๋ฃน๋‹ˆ๋‹ค.

AML (Acute Myeloid Leukemia) โ€” Myeloblast ๋‹จ๊ณ„์—์„œ ๋ถ„ํ™” ์ฐจ๋‹จ, ๊ณจ์ˆ˜์— blast ์ถ•์ . ๋™์ธ ๋ณ€์ด๋Š” FLT3-ITD, NPM1, IDH1/2, TP53. 2022 ELN/Dรถhner et al. Blood ์ง„๋‹จ ๋ฐ ๊ด€๋ฆฌ ํ”„๋ ˆ์ž„์›Œํฌ๋Š” ํ˜„์žฌ ์ž„์ƒ ์‹ค๋ฌด์—์„œ ์‚ฌ์šฉ๋˜๋Š” ๋ถ„์ž ๋ถ„๋ฅ˜๋ฅผ ์ •์˜ํ•ฉ๋‹ˆ๋‹ค.
MDS (Myelodysplastic Syndromes) โ€” ์ดํ˜•์„ฑ ํ˜•ํƒœํ•™์„ ๊ฐ€์ง„ ๋น„ํšจ์œจ์  ์กฐํ˜ˆ, ๋ง์ดˆ cytopenia, AML ํ˜•์งˆ์ „ํ™˜ ์œ„ํ—˜ ์ฆ๊ฐ€. ์ข…์ข… ์ˆ˜์‹ญ ๋…„์— ๊ฑธ์ณ ์ถ•์ ๋œ ์ž ์žฌ๋ ฅ ๋ฏธ์ƒ์˜ ํด๋ก  ์กฐํ˜ˆ(CHIP)์—์„œ ๋ฐœ์ƒ.
MPN (Myeloproliferative Neoplasms) โ€” JAK2 V617F(๊ฐ€์žฅ ํ”ํ•จ, polycythemia vera์˜ ~95%, essential thrombocythemia์™€ primary myelofibrosis์˜ 50-60%), CALR ๋˜๋Š” MPL์˜ ๋™์ธ ๋ณ€์ด๊ฐ€ ๊ตฌ์„ฑ์  JAK/STAT ์‹ ํ˜ธ์™€ erythroid, megakaryocytic ๋˜๋Š” granulocytic ๊ณ„ํ†ต์˜ ๊ณผ์ž‰ ์ƒ์‚ฐ์„ ์ผ์œผํ‚ด. Levine et al. 2007 Nat Rev Cancer MPN์˜ JAK2 ๋ฆฌ๋ทฐ๋Š” ๊ฒฐ์ •์  ์ฐธ์กฐ๋กœ ๋‚จ์•„ ์žˆ์Œ.
๊ณจ์ˆ˜ ๋ถ€์ „ ๋ฐ ์žฌ์ƒ๋ถˆ๋Ÿ‰์„ฑ ๋นˆํ˜ˆ โ€” ์ž๊ฐ€๋ฉด์—ญ ๊ณต๊ฒฉ, ์œ ์ „ ๋ณ€์ด ๋˜๋Š” ํ™˜๊ฒฝ ์นจํ•ด๋กœ๋ถ€ํ„ฐ HSC ๊ณ ๊ฐˆ. Niche๋Š” ์˜จ์ „ํ•˜์ง€๋งŒ ๋น„์–ด ์žˆ์Œ.
์งˆ๋ณ‘์กฐํ˜ˆ ๊ฒฐํ•จ์ฃผ์š” ๋™์ธ ๋ณ€์ด๊ณ„ํ†ต์ƒ ์œ„์น˜
AMLMyeloblast์—์„œ ๋ถ„ํ™” ์ฐจ๋‹จFLT3-ITD, NPM1, IDH1/2, TP53CMP/GMP ํ•˜๋ฅ˜์˜ Myeloid ์ปค๋ฐ‹๋จผํŠธ
MDS๋น„ํšจ์œจ์  ์กฐํ˜ˆ + cytopeniaDNMT3A, TET2, SF3B1, ASXL1๋‹ค๊ณ„ํ†ต ๊ด€์—ฌ๊ฐ€ ์žˆ๋Š” HSC/MPP
MPN์„ฑ์ˆ™ myeloid ๊ณ„ํ†ต ๊ณผ์ž‰ ์ƒ์‚ฐJAK2 V617F (~95% PV), CALR, MPLJAK/STAT ๊ณผํ™œ์„ฑํ™”๊ฐ€ ์žˆ๋Š” HSC
CHIP/CCUS๋ช…๋ฐฑํ•œ ์งˆํ™˜ ์—†๋Š” ํด๋ก  ํ™•์žฅDNMT3A, TET2, ASXL1HSC, MDS/AML์˜ ์ „๊ตฌ ์ƒํƒœ
์žฌ์ƒ๋ถˆ๋Ÿ‰์„ฑ ๋นˆํ˜ˆHSC ๊ณ ๊ฐˆ โ†’ ๋นˆ ๊ณจ์ˆ˜์ข…์ข… ํ›„์ฒœ์„ฑ/์ž๊ฐ€๋ฉด์—ญ (PNH ์ค‘์ฒฉ)HSC pool ๋ถ•๊ดด

Tip

์ด๋Ÿฌํ•œ ์งˆ๋ณ‘ ์ƒํƒœ ์ค‘ ๋‘ ๊ฐ€์ง€ ์ด์ƒ์„ ๋น„๊ตํ•˜๋Š” ํฌ์Šคํ„ฐ(์˜ˆ: MDS-to-AML ์ง„ํ–‰ ๋˜๋Š” CHIP-to-MDS ์ง„ํ™”)์˜ ๊ฒฝ์šฐ, ๊ฐ ์งˆ๋ณ‘์˜ ๊ณ„ํ†ต์„ ๋ณ„๋„๋กœ ๊ทธ๋ฆฌ๋Š” ๋Œ€์‹  ๊ฐ ์งˆ๋ณ‘์˜ ๋ณ‘๋ณ€ ์ง€์ ์ด ์ƒ‰์ƒ ๊ฐ•์กฐ๋กœ ์ฃผ์„๋œ ๋‹จ์ผ ๊ณต์œ  ๊ณ„ํ†ต ๋„ํ˜•์„ ๋งŒ๋“œ์„ธ์š”. ์‹ฌ์‚ฌ์œ„์›์€ ๊ณต์œ  ์Šค์บํด๋“œ๋ฅผ ๋” ๋นจ๋ฆฌ ํก์ˆ˜ํ•˜๊ณ , ์—ฌ๋Ÿฌ ํฌ์Šคํ„ฐ ํŒจ๋„์— ๊ฑธ์ณ ๋™์ผํ•œ SciFig ์›๋ณธ ๋„ํ˜•์„ ์žฌ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
AML ๋ถ„ํ™” ์ฐจ๋‹จ: FLT3-ITD, NPM1, IDH1/2, TP53 ๋ณ€์ด๋กœ myeloblast์—์„œ myeloid ์„ฑ์ˆ™ ์ •์ง€ (SciFig์œผ๋กœ ์ƒ์„ฑ๋œ ๊ทธ๋ฆผ)
AML ๋ถ„ํ™” ์ฐจ๋‹จ: FLT3-ITD, NPM1, IDH1/2, TP53 ๋ณ€์ด๋กœ myeloblast์—์„œ myeloid ์„ฑ์ˆ™ ์ •์ง€ (SciFig์œผ๋กœ ์ƒ์„ฑ๋œ ๊ทธ๋ฆผ)
MPN ๋ณ‘ํƒœ๋ฐœ์ƒ: HSC์˜ JAK2 V617F โ†’ ๊ตฌ์„ฑ์  JAK/STAT ์‹ ํ˜ธ โ†’ PV, ET, PMF ๊ณ„ํ†ต ๊ณผ์ž‰ ์ƒ์‚ฐ (SciFig์œผ๋กœ ์ƒ์„ฑ๋œ ๊ทธ๋ฆผ)
MPN ๋ณ‘ํƒœ๋ฐœ์ƒ: HSC์˜ JAK2 V617F โ†’ ๊ตฌ์„ฑ์  JAK/STAT ์‹ ํ˜ธ โ†’ PV, ET, PMF ๊ณ„ํ†ต ๊ณผ์ž‰ ์ƒ์‚ฐ (SciFig์œผ๋กœ ์ƒ์„ฑ๋œ ๊ทธ๋ฆผ)
ํด๋ก  ์กฐํ˜ˆ์„ ๊ตฌ์ฒด์ ์œผ๋กœ ๋‹ค๋ฃจ๋Š” ํฌ์Šคํ„ฐ์˜ ๊ฒฝ์šฐ, ์งˆํ™˜ ์ŠคํŽ™ํŠธ๋Ÿผ์€ CHIP(๊ฑด๊ฐ•ํ•œ ๋…ธํ™”์—์„œ ๊ฒ€์ถœ ๊ฐ€๋Šฅํ•œ ๋ณ€์ด HSC ํด๋ก )์—์„œ CCUS(๋ถˆํ™•์ • ์˜์˜์˜ ํด๋ก  cytopenia)๋ฅผ ๊ฑฐ์ณ MDS์™€ AML๋กœ ํ™•์žฅ๋ฉ๋‹ˆ๋‹ค โ€” ์ง„ํ–‰ ํƒ€์ž„๋ผ์ธ์œผ๋กœ ์‹œ๊ฐํ™”๋˜์–ด์•ผ ํ•˜๋Š” ์—ฐ์†์ฒด. Jaiswal๊ณผ Ebert 2019 Science์˜ CHIP ๋ฆฌ๋ทฐ๊ฐ€ ์ด๋ฅผ ์ž„์ƒ์ ์œผ๋กœ ๊ตฌ์„ฑํ•ฉ๋‹ˆ๋‹ค.
ํด๋ก  ์กฐํ˜ˆ ์ง„ํ–‰: ์—ฐ๋ น์— ๋”ฐ๋ฅธ DNMT3A, TET2, ASXL1 ๋™์ธ ๋ณ€์ด๋กœ CHIP โ†’ CCUS โ†’ MDS โ†’ AML (SciFig์œผ๋กœ ์ƒ์„ฑ๋œ ๊ทธ๋ฆผ)
ํด๋ก  ์กฐํ˜ˆ ์ง„ํ–‰: ์—ฐ๋ น์— ๋”ฐ๋ฅธ DNMT3A, TET2, ASXL1 ๋™์ธ ๋ณ€์ด๋กœ CHIP โ†’ CCUS โ†’ MDS โ†’ AML (SciFig์œผ๋กœ ์ƒ์„ฑ๋œ ๊ทธ๋ฆผ)

8. AI ๊ธฐ๋ฐ˜ ์กฐํ˜ˆ ๋‹ค์ด์–ด๊ทธ๋žจ: ์ค„๊ธฐ์„ธํฌ ํฌ์Šคํ„ฐ๋ฅผ ์œ„ํ•œ SciFig ์›Œํฌํ”Œ๋กœ

์กฐํ˜ˆ ํŠธ๋ฆฌ, niche ๋„ํ˜•, ์งˆํ™˜ ๊ณ„ํ†ต ๋‹ค์ด์–ด๊ทธ๋žจ์ด "ํ•œ ์ฃผ๋ฅผ ๋ง‰๋Š” ๊ฒƒ"์—์„œ "์ ์‹ฌ ์ „์— ์ดˆ์•ˆ ์™„์„ฑ"์œผ๋กœ ๊ฐ€๋Š” ๋ถ€๋ถ„์ด๋ฉฐ โ€” ์ผ๋ฐ˜ AI๊ฐ€ ์ด ํŠน์ • ์ข…๋ฅ˜์˜ ๋„ํ˜•์— ๊ตฌ์กฐ์ ์œผ๋กœ ๋ถ€์ ํ•ฉํ•œ ์ด์œ ๋„ ์•Œ๊ฒŒ ๋˜๋Š” ๋ถ€๋ถ„์ž…๋‹ˆ๋‹ค.

GPT image๋‚˜ Midjourney๋กœ ์กฐํ˜ˆ ํŠธ๋ฆฌ๋ฅผ ์ƒ์„ฑํ•ด ๋ณธ ์ ์ด ์žˆ๋‹ค๋ฉด ๊ฒฐ๊ณผ๋ฅผ ๋ดค์„ ๊ฒƒ์ž…๋‹ˆ๋‹ค. ๋ชจ๋ธ์ด ๋Œ€๋žต์ ์ธ ์ˆ˜์ง ๋ ˆ์ด์•„์›ƒ์€ ์–ป์ง€๋งŒ myeloid-lymphoid ๋ถ„๊ธฐ๋ฅผ ๋’ค์ง‘๊ฑฐ๋‚˜, megakaryocyte๋ฅผ CLP ์•„๋ž˜์— ๋†“๊ฑฐ๋‚˜, ์–ด๋–ค ๋ถ„๋ฅ˜ํ•™์—๋„ ์‹ค์ œ๋กœ ์กด์žฌํ•˜์ง€ ์•Š๋Š” ์ž์‹ ๊ฐ ์žˆ๊ฒŒ ๋ผ๋ฒจ๋œ "CD34+ E-progenitor" ์„ธํฌ ์œ ํ˜•์„ ์ƒ์„ฑํ•ฉ๋‹ˆ๋‹ค. ๋‹ค์‹œ ๊ตด๋ฆฌ๋ฉด ๋‹ค์Œ ๋ฒ„์ „์€ ํ† ํด๋กœ์ง€๊ฐ€ ๋Œ€๋ถ€๋ถ„ ์ •ํ™•ํ•˜์ง€๋งŒ niche ์„ธํฌ ๋ผ๋ฒจ์„ ์žƒ๊ฑฐ๋‚˜ erythrocyte๊ฐ€ lymphoid ๊ณ„ํ†ต์—์„œ ๋ถ„๊ธฐ๋˜๋Š” ๊ฒƒ์œผ๋กœ ๊ทธ๋ฆฝ๋‹ˆ๋‹ค. ์ด๋Š” ํŠน์ • ๋ฒค๋”์˜ ๋ฌธ์ œ๊ฐ€ ์•„๋‹™๋‹ˆ๋‹ค โ€” ์˜ค๋Š˜๋‚  ์–ด๋–ค ์ผ๋ฐ˜ ์ด๋ฏธ์ง€ ๋ชจ๋ธ๋„ ์ฒซ ์‹œ๋„์—์„œ ์กฐํ˜ˆ ํ† ํด๋กœ์ง€๋ฅผ ์•ˆ์ •์ ์œผ๋กœ ์ •ํ™•ํžˆ ์–ป์„ ์ˆ˜ ์—†์Šต๋‹ˆ๋‹ค. ๋ชจ๋ธ์ด ํ•œ ๋ถ„๊ธฐ๊ฐ€ ๋’ค์ง‘ํžˆ๋ฉด ์ „์ฒด ๊ณ„ํ†ต ์ถ”๋ก ์„ ๋ฌดํšจํ™”ํ•œ๋‹ค๋Š” ๊ฒƒ์„ ์ดํ•ดํ•˜์ง€ ์•Š๊ณ  "ํ˜ˆ์•ก ์„ธํฌ์˜ ํŠธ๋ฆฌ"๋ฅผ ์‹œ๊ฐ์ ์œผ๋กœ ํ•ด์„ํ•˜๊ธฐ ๋•Œ๋ฌธ์ž…๋‹ˆ๋‹ค. ๊ทธ๋ฆฌ๊ณ  ํ˜ˆ์•กํ•™ ํฌ์Šคํ„ฐ์˜ ๊ฒฝ์šฐ, ํ•œ ๋ถ„๊ธฐ๊ฐ€ ์ž˜๋ชป๋œ ํŠธ๋ฆฌ๋Š” ํŠธ๋ฆฌ๊ฐ€ ์—†๋Š” ๊ฒƒ๋ณด๋‹ค ๋‚˜์ฉ๋‹ˆ๋‹ค โ€” ์—ฐ๊ตฌํ•˜๊ณ  ์žˆ๋Š” ์„ธํฌ ์ƒ๋ฌผํ•™์— ๋Œ€ํ•ด ์‹ฌ์‚ฌ์œ„์›์„ ์ ๊ทน์ ์œผ๋กœ ์˜ค๋„ํ•ฉ๋‹ˆ๋‹ค.
SciFig๋Š” ์ •ํ™•ํžˆ ์ด ๊ฒฉ์ฐจ๋ฅผ ์œ„ํ•ด ๋งŒ๋“ค์–ด์กŒ์Šต๋‹ˆ๋‹ค. ๋™๊ธ‰ ์ตœ๊ณ ์˜ ์ด๋ฏธ์ง€ ์ƒ์„ฑ ๋ชจ๋ธ์€ ์ฒซ ํŒจ์Šค ํŠธ๋ฆฌ๋ฅผ ๊ณ ์ถฉ์‹ค๋„ ์‹œ์ž‘์ ์œผ๋กœ ๊ฐ€์ ธ์˜ต๋‹ˆ๋‹ค โ€” HSC โ†’ MPP โ†’ CMP/CLP ํ† ํด๋กœ์ง€, ์ฃผ์š” ์ค‘๊ฐ„ progenitor, 11๊ฐ€์ง€ ์„ฑ์ˆ™ ๊ณ„ํ†ต โ€” ๋Œ€๋ถ€๋ถ„ ์ฒซ ์ดˆ์•ˆ์—์„œ ์ •ํ™•ํ•ฉ๋‹ˆ๋‹ค. ๊ทธ๋Ÿฌ๋‚˜ ๊ฐ€์žฅ ์ค‘์š”ํ•œ ์ •๋ฐ€ ์„ธ๋ถ€์‚ฌํ•ญ โ€” CMP๊ฐ€ CLP๊ฐ€ ์•„๋‹Œ MPP์—์„œ ๋‚ด๋ ค์˜ค๋Š”์ง€ ํ™•์ธ, MEP๊ฐ€ erythrocyte์™€ megakaryocyte๋ฅผ ๋‚ณ๋Š”์ง€ ํ™•์ธ, JAK/STAT ์บ์Šค์ผ€์ด๋“œ๊ฐ€ ์˜ฌ๋ฐ”๋ฅธ ๋ฐฉํ–ฅ(cytokine โ†’ JAK โ†’ STAT ์ธ์‚ฐํ™” โ†’ ์ดํ•ฉ์ฒดํ™” โ†’ ํ•ต ์ „์œ„)์œผ๋กœ ํ๋ฅด๋Š”์ง€ ํ™•์ธ โ€” ์˜ ๊ฒฝ์šฐ, ๋ธŒ๋ผ์šฐ์ €์˜ ํŽธ์ง‘ ๊ฐ€๋Šฅํ•œ ๋ฒกํ„ฐ ์บ”๋ฒ„์Šค์—์„œ ์–ด๋–ค progenitor ๋ผ๋ฒจ์ด๋“  ํด๋ฆญํ•ด ์ด๋ฆ„์„ ๋ฐ”๊พธ๊ณ , ์–ด๋–ค ๋ถ„๊ธฐ๋“  ๋“œ๋ž˜๊ทธํ•ด ์žฌ๋ฐฐ์น˜ํ•˜๊ณ , ์ „์ฒด ํŠธ๋ฆฌ๋ฅผ ๋‹ค์‹œ ๊ตด๋ฆฌ์ง€ ์•Š๊ณ  ํ•œ ํ™”์‚ดํ‘œ๋ฅผ ์ˆ˜์ •ํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ๋‚จ์€ ์ •๋ฐ€ ๊ฒฉ์ฐจ๋Š” ๋ถ„์ด ์•„๋‹Œ ์ดˆ ๋‹จ์œ„๋กœ ๋‹ซํž™๋‹ˆ๋‹ค. ๊ทธ๋ฆฌ๊ณ  ์ „์ฒด ์›Œํฌํ”Œ๋กœ๊ฐ€ SciFig ์•ˆ์— ๋จธ๋ญ…๋‹ˆ๋‹ค โ€” ์‹คํ—˜์‹ค ๋ฏธํŒ…์šฉ ํŽธ์ง‘ ๊ฐ€๋Šฅํ•œ PPTX, ๋‹ค์šด์ŠคํŠธ๋ฆผ ํŽธ์ง‘์šฉ ๋ ˆ์ด์–ด SVG, ๋˜๋Š” A0 ํฌ์Šคํ„ฐ ์ธ์‡„์šฉ 8K PNG๋กœ ํ•œ ๋ฒˆ์˜ ํด๋ฆญ ๋‚ด๋ณด๋‚ด๊ธฐ, ์•„ํ‹ฐํŒฉํŠธ ์—†์ด. "ํŠธ๋ฆฌ ํ† ํด๋กœ์ง€ ์ˆ˜์ •"์„ ์œ„ํ•œ Illustrator ์™•๋ณต์€ ์—†์Šต๋‹ˆ๋‹ค. ์ƒ์„ฑ๋œ ๊ทธ ์ž๋ฆฌ์—์„œ ์ˆ˜์ •ํ•˜๊ธฐ ๋•Œ๋ฌธ์ž…๋‹ˆ๋‹ค.

๊ฒฝ๋กœ๋Š” ์ด๋ ‡์Šต๋‹ˆ๋‹ค. ์ •๊ทœ ์กฐํ˜ˆ ํŠธ๋ฆฌ๋ฅผ ์‹œ์ž‘ํ•˜๊ธฐ ์œ„ํ•ด ์ด ํ”„๋กฌํ”„ํŠธ๋ฅผ SciFig์˜ Text-to-Figure ๋„๊ตฌ์— ๊ทธ๋Œ€๋กœ ๋ณต์‚ฌํ•˜์„ธ์š”.

Comprehensive hematopoiesis differentiation tree starting from
hematopoietic stem cell (HSC) at top, branching to multipotent
progenitor (MPP), then bifurcating into common myeloid progenitor
(CMP) on the left and common lymphoid progenitor (CLP) on the right.
CMP gives rise to MEP (erythrocytes, megakaryocytes/platelets) and
GMP (neutrophils, eosinophils, basophils, monocytes/macrophages,
dendritic cells, mast cells). CLP gives rise to T cells, B cells,
NK cells. Vertical layout, color-coded by lineage, accurate cell
morphology, publication-ready style.
์—ฐ๊ตฌ์— ๋งž๊ฒŒ ์กฐ์ •ํ•˜์„ธ์š” โ€” ๋‹ค๋ฃจ์ง€ ์•Š๋Š” ๊ณ„ํ†ต์€ ์ถ•์†Œํ•˜๊ณ , ์ž‘์—…์˜ ์ค‘์‹ฌ์— ์žˆ๋Š” ์ค‘๊ฐ„ progenitor๋Š” ํ™•์žฅํ•˜๊ณ , ์ค‘์žฌ๊ฐ€ ํ‘œ์ ์œผ๋กœ ํ•˜๋Š” ํŠน์ • ๊ณ„ํ†ต ๊ฒฐ์ • ์ง€์ ์— ์ฃผ์„์„ ๋‹ค์„ธ์š”. ๋ชจ๋ธ์€ ๋ช‡ ์ดˆ ์•ˆ์— ์‹œ์ž‘ ํŠธ๋ฆฌ๋ฅผ ๋งŒ๋“ค์–ด๋‚ด๋ฉฐ, SciFig ๋ฒกํ„ฐ ์บ”๋ฒ„์Šค์—์„œ ๋‹ค์‹œ ๊ตด๋ฆฌ์ง€ ์•Š๊ณ  ๊ฐ progenitor ๋ผ๋ฒจ์„ ๊ฐœ๋ณ„์ ์œผ๋กœ ๋‹ค๋“ฌ์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

๊ณจ์ˆ˜ niche, JAK/STAT ๊ฒฝ๋กœ, AML ๋ถ„ํ™” ์ฐจ๋‹จ, MPN JAK2 ๋„ํ˜•, CHIP ์ง„ํ™” ํƒ€์ž„๋ผ์ธ์˜ ๊ฒฝ์šฐ โ€” ์•„๋ž˜ 9์žฅ์˜ ํ”„๋กฌํ”„ํŠธ๋ฅผ ๋ณต์‚ฌํ•˜์„ธ์š”.

AI ๊ณผํ•™ ๊ทธ๋ฆผ ์ƒ์„ฑ์„ ์ง์ ‘ ํ™•์ธํ•˜์„ธ์š”

์—ฐ๊ตฌ์ž๋“ค์ด ํ…์ŠคํŠธ ์„ค๋ช…๋งŒ์œผ๋กœ ์ถœํŒ ๊ฐ€๋Šฅํ•œ ๊ณผํ•™ ๋„ํ˜•์„ ๋งŒ๋“œ๋Š” ๊ณผ์ •์„ ํ™•์ธํ•˜์„ธ์š”.

๋„๊ตฌ ์‚ดํŽด๋ณด๊ธฐ

9. ๋ฌด๋ฃŒ ์ฒดํ—˜ CTA + ๊ด€๋ จ ์ฝ๊ธฐ ์ž๋ฃŒ: 5๊ฐ€์ง€ ๋ณต์‚ฌ-๋ถ™์—ฌ๋„ฃ๊ธฐ ์กฐํ˜ˆ ํ”„๋กฌํ”„ํŠธ

์ด ๊ธ€์—์„œ ๋ณด์—ฌ์ค€ ๋„ํ˜•๋“ค์˜ 5๊ฐ€์ง€ ๋‚จ์€ SciFig ํ”„๋กฌํ”„ํŠธ. ์–ด๋А ๊ฒƒ์ด๋“  Text-to-Figure์— ์ง์ ‘ ๋ณต์‚ฌํ•˜์„ธ์š”.

์กฐํ˜ˆ ํŠธ๋ฆฌ โ€” ์œ„ 8์žฅ ์ฐธ์กฐ.
๊ณจ์ˆ˜ niche:
Cross-section of bone marrow microenvironment showing HSC niche:
vascular niche near sinusoids with endothelial cells, perivascular
niche with mesenchymal stromal cells (MSC) and CXCL12-abundant
reticular (CAR) cells, osteoblastic niche near bone surface,
sympathetic nerve fibers regulating egress. HSC quiescence vs
mobilization shown.
HSC ์‹ ํ˜ธ ๊ฒฝ๋กœ:
HSC self-renewal vs differentiation signaling: SCF-c-Kit, Wnt/ฮฒ-catenin,
Notch, JAK/STAT (TPO-MPL), TGF-ฮฒ quiescence. Show cell membrane,
cytoplasmic cascade, nuclear transcription factors (GATA1, PU.1,
RUNX1 lineage commitment). Annotate signaling direction with arrows.
AML ๋ถ„ํ™” ์ฐจ๋‹จ:
AML pathogenesis: normal myeloid differentiation arrow blocked at
myeloblast stage. Show accumulation of CD34+ blasts in bone marrow,
compared to healthy hematopoiesis. Key mutations annotated:
FLT3-ITD, NPM1, IDH1/2, TP53.
MPN JAK2 V617F:
Myeloproliferative neoplasm pathogenesis: JAK2 V617F gain-of-function
mutation in HSC produces constitutive JAK/STAT signaling, leading to
overproduction of erythroid, megakaryocytic, and granulocytic
lineages. Show resulting PV (polycythemia vera), ET (essential
thrombocythemia), and PMF (primary myelofibrosis) phenotypes.
ํด๋ก  ์กฐํ˜ˆ ์ง„ํ™”:
Clonal hematopoiesis progression: CHIP (clonal hematopoiesis of
indeterminate potential) โ†’ CCUS (clonal cytopenias of undetermined
significance) โ†’ MDS โ†’ AML. Show clonal expansion of mutated HSC
over age, with DNMT3A, TET2, ASXL1 driver mutations annotated.
Horizontal timeline format.
์ƒˆ SciFig ๊ณ„์ •์€ 150 starter credits์™€ ๋งค์ผ 50 refill credits๋กœ ์‹œ์ž‘ํ•ฉ๋‹ˆ๋‹ค. ์ด ๊ธ€์˜ 6๊ฐ€์ง€ ๋„ํ˜• โ€” ์กฐํ˜ˆ ํŠธ๋ฆฌ, niche, ์‹ ํ˜ธ, AML ์ฐจ๋‹จ, MPN, CHIP ์ง„ํ™” โ€” ์€ ๋ฐ˜๋ณต์„ ํฌํ•จํ•ด ๋ณดํ†ต 50~80 credits๋ฅผ ์†Œ๋น„ํ•ฉ๋‹ˆ๋‹ค. starter pack์ด ๋‹ค๋“ฌ๊ธฐ๋ฅผ ์œ„ํ•œ daily refill ์—ฌ์œ ์™€ ํ•จ๊ป˜ ์ „์ฒด ์กฐํ˜ˆ ๋„ํ˜• ์„ธํŠธ๋ฅผ ์ปค๋ฒ„ํ•ฉ๋‹ˆ๋‹ค. 1๋…„์— ๊ฑธ์ณ ์—ฌ๋Ÿฌ ํฌ์Šคํ„ฐ์˜ ๋„ํ˜•์„ ๋งŒ๋“ค ๊ฒƒ์œผ๋กœ ์˜ˆ์ƒ๋˜๋ฉด pricing ํŽ˜์ด์ง€๋ฅผ ์ฐธ๊ณ ํ•˜์„ธ์š”.
EHA ํฌ์Šคํ„ฐ ํ˜•์‹๊ณผ ๋„ค ๊ฐ€์ง€ ๋ฐœํ‘œ ๋‹จ๊ณ„์˜ ๊ธฐ๋ณธ์€ EHA 2026 ํฌ์Šคํ„ฐ ๊ฐ€์ด๋“œ๋ผ์ธ๊ณผ ํ…œํ”Œ๋ฆฟ์—์„œ ์‹œ์ž‘ํ•˜์„ธ์š”. ์šฐ์Šน ํฌ์Šคํ„ฐ์™€ ํ‰๊ท  ํฌ์Šคํ„ฐ๋ฅผ ๊ตฌ๋ถ„ํ•˜๋Š” ๋””์ž์ธ ์›์น™์€ EHA 2026 ์šฐ์Šน ํฌ์Šคํ„ฐ ๋””์ž์ธํ•˜๊ธฐ๋ฅผ ์ฐธ๊ณ ํ•˜์„ธ์š”. ์—ฐ๊ตฌ๊ฐ€ ํ˜ˆ์•กํ•™์  ์•…์„ฑ์ข…์–‘์„ ํ‘œ์ ํ•˜๋Š” CAR-T ์„ธํฌ ๋ฉด์—ญ์น˜๋ฃŒ์—๋„ ๋‹ฟ๋Š”๋‹ค๋ฉด, ๋™๋ฐ˜ ๊ธ€ EHA 2026 ํฌ์Šคํ„ฐ์šฉ CAR-T ๋ฉ”์ปค๋‹ˆ์ฆ˜ ์ผ๋Ÿฌ์ŠคํŠธ๋ ˆ์ด์…˜์ด ๋™์ผํ•œ ์งˆํ™˜ ๊ณต๊ฐ„์˜ ์กฐ์ž‘๋œ T ์„ธํฌ ์ธก๋ฉด์„ ๋‹ค๋ฃน๋‹ˆ๋‹ค.
(์œ„์—์„œ ์ฐธ์กฐ๋œ JAK/STAT ๋ฐ Notch ์บ์Šค์ผ€์ด๋“œ๋ฅผ ํฌํ•จํ•ด) ์–ด๋–ค ์„ธํฌ ์‹ ํ˜ธ ๊ฒฝ๋กœ ๋„ํ˜•์ด๋“  ๋งŒ๋“œ๋Š” ๊ณ„์ธต ์ ‘๊ทผ๋ฒ•์€ AI๋กœ ์„ธํฌ ์‹ ํ˜ธ ์ „๋‹ฌ ๊ฒฝ๋กœ ๋‹ค์ด์–ด๊ทธ๋žจ ๋งŒ๋“ค๊ธฐ ์›Œํฌ์Šค๋ฃจ๋ฅผ ์ฐธ๊ณ ํ•˜์„ธ์š”.

์ง€๊ธˆ ๊ณผํ•™ ๋„ํ˜• ๋งŒ๋“ค๊ธฐ

๊ณผํ•™ ๋„ํ˜•์„ ์ž์—ฐ์–ด๋กœ ์„ค๋ช…ํ•˜์„ธ์š” โ€” ์ถœํŒ ๊ฐ€๋Šฅํ•œ ์ผ๋Ÿฌ์ŠคํŠธ๋ฅผ ๋‹จ ๋ช‡ ๋ถ„ ๋งŒ์— ๋ฐ›์•„๋ณด์„ธ์š”.

Try ๋ฌด๋ฃŒ

FAQ


๋ฉด์ฑ… ์กฐํ•ญ: ๋ณธ ๊ธ€์€ ํ•™์ˆ  ํฌ์Šคํ„ฐ ๋ฐ ๋…ผ๋ฌธ ๋ฐœํ‘œ๋ฅผ ์œ„ํ•œ ๊ณผํ•™ ์ผ๋Ÿฌ์ŠคํŠธ ๋””์ž์ธ ๊ต์œก ์ฝ˜ํ…์ธ ์ด๋ฉฐ, ์˜ํ•™์  ์กฐ์–ธ์„ ๊ตฌ์„ฑํ•˜์ง€ ์•Š์œผ๋ฉฐ ์ž„์ƒ ์˜์‚ฌ ๊ฒฐ์ •์— ์‚ฌ์šฉํ•ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค. ๋ณธ ๊ธ€์—์„œ ์„ค๋ช…ํ•œ ์งˆ๋ณ‘ ๋ฉ”์ปค๋‹ˆ์ฆ˜, ์•ฝ๋ฌผ ์ ์‘์ฆ, ์น˜๋ฃŒ ํ”„๋กœํ† ์ฝœ์€ ์œ„์—์„œ ์ธ์šฉ๋œ ๋™๋ฃŒ ์‹ฌ์‚ฌ ์ž๋ฃŒ์—์„œ ์š”์•ฝํ•œ ๊ฒƒ์ž…๋‹ˆ๋‹ค. ์ž„์ƒ ์‹ค๋ฌด๋ฅผ ์œ„ํ•ด์„œ๋Š” ์›๋ณธ ๋ฌธํ—Œ, ๊ณต์‹ ์น˜๋ฃŒ ๊ฐ€์ด๋“œ๋ผ์ธ(NCCN / ESMO / ASH ๋“ฑ), ๊ทธ๋ฆฌ๊ณ  ๋ฉดํ—ˆ๋ฅผ ๊ฐ€์ง„ ์ž„์ƒ์˜์—๊ฒŒ ๋ฌธ์˜ํ•˜์‹ญ์‹œ์˜ค. SciFig๋Š” ๊ณผํ•™ ์ผ๋Ÿฌ์ŠคํŠธ ๋„๊ตฌ๋กœ, ์ง„๋‹จ, ์น˜๋ฃŒ ๋˜๋Š” ํ™˜์ž ์ง„๋ฃŒ์— ๋Œ€ํ•œ ์กฐ์–ธ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
SciFig Team

SciFig Team

Scientific Illustration Experts

Building AI-powered tools that help researchers create publication-quality scientific illustrations.

SciFig ์‚ฌ์šฉํ•ด๋ณด๊ธฐ

์—ฐ๊ตฌ์ž๋ฅผ ์œ„ํ•œ ๋„๊ตฌ

  • Text-to-Figure ์ƒ์„ฑ
  • Sketch-to-Figure ๋ณ€ํ™˜
  • ๋ฒกํ„ฐ / SVG / PPT ๋‚ด๋ณด๋‚ด๊ธฐ
  • ์‹œ์ž‘์— 200 ๋ฌด๋ฃŒ ํฌ๋ ˆ๋”ง
๋ฌด๋ฃŒ๋กœ ์‹œ์ž‘ํ•˜๊ธฐ๊ฐ€๊ฒฉ ๋ณด๊ธฐ โ†’

์‹ ์šฉ์นด๋“œ ํ•„์š” ์—†์Œ

๊ณ„์† ์ฝ๊ธฐ

EHA 2026 ํฌ์Šคํ„ฐ์šฉ CAR-T ๋ฉ”์ปค๋‹ˆ์ฆ˜ ์ผ๋Ÿฌ์ŠคํŠธ๋ ˆ์ด์…˜
ํŠœํ† ๋ฆฌ์–ผ33 min read

EHA 2026 ํฌ์Šคํ„ฐ์šฉ CAR-T ๋ฉ”์ปค๋‹ˆ์ฆ˜ ์ผ๋Ÿฌ์ŠคํŠธ๋ ˆ์ด์…˜

EHA 2026 ํฌ์Šคํ„ฐ์šฉ ์ถœํŒ ์ค€๋น„ CAR-T ๋ฉ”์ปค๋‹ˆ์ฆ˜ ๋‹ค์ด์–ด๊ทธ๋žจ ์ž‘์„ฑ: 5๊ฐ€์ง€ ์‹œ๊ฐ ๊ตฌ์„ฑ ์š”์†Œ, 4์„ธ๋Œ€ CAR, BiTE ๊ณ„์—ด, ๋ณต์‚ฌ-๋ถ™์—ฌ๋„ฃ๊ธฐ AI ํ”„๋กฌํ”„ํŠธ.

SciFig TeamSciFig Teamยท2026-05-22
AI๋กœ ์„ธํฌ ์‹ ํ˜ธ ์ „๋‹ฌ ๊ฒฝ๋กœ ๋‹ค์ด์–ด๊ทธ๋žจ ๋งŒ๋“ค๊ธฐ
ํŠœํ† ๋ฆฌ์–ผ20 min read

AI๋กœ ์„ธํฌ ์‹ ํ˜ธ ์ „๋‹ฌ ๊ฒฝ๋กœ ๋‹ค์ด์–ด๊ทธ๋žจ ๋งŒ๋“ค๊ธฐ

์ถœํŒ ์ค€๋น„๋œ ์„ธํฌ ์‹ ํ˜ธ ์ „๋‹ฌ ๊ฒฝ๋กœ ๋‹ค์ด์–ด๊ทธ๋žจ์„ ๋ช‡ ๋ถ„ ์•ˆ์— ๋งŒ๋“œ๋Š” 3๊ฐ€์ง€ AI ๋ฐฉ๋ฒ• โ€” ํ…์ŠคํŠธ์—์„œ ๊ทธ๋ฆผ, ์Šค์ผ€์น˜์—์„œ ๊ทธ๋ฆผ ๋ฐ SVG ๋ฒกํ„ฐ ๋‚ด๋ณด๋‚ด๊ธฐ.

SciFig TeamSciFig Teamยท2026-01-29
AI ํ…์ŠคํŠธ์—์„œ ๊ทธ๋ฆผ์œผ๋กœ ์—ฐ๊ตฌ ์ฆ‰์‹œ ์‹œ๊ฐํ™”
ํŠœํ† ๋ฆฌ์–ผ32 min read

AI ํ…์ŠคํŠธ์—์„œ ๊ทธ๋ฆผ์œผ๋กœ ์—ฐ๊ตฌ ์ฆ‰์‹œ ์‹œ๊ฐํ™”

ํ…์ŠคํŠธ์—์„œ ๊ทธ๋ฆผ์ด ์–ด๋–ป๊ฒŒ ์„ค๋ช…์„ ๋ช‡ ์ดˆ ๋งŒ์— ์ถœํŒ ์ค€๋น„๋œ ์—ฐ๊ตฌ ๋„ํ˜•์œผ๋กœ ๋ณ€ํ™˜ํ•˜๋Š”์ง€.

SciFig TeamSciFig Teamยท2026-01-25
์ฝœํˆฌ์•ก์…˜ ๋ฐฐ๊ฒฝ

์‹œ์ž‘ํ•  ์ค€๋น„๊ฐ€ ๋˜์…จ๋‚˜์š”?

์ถœํŒ ๊ฐ€๋Šฅํ•œ ๊ณผํ•™ ๋„ํ˜•, ๋‹จ ๋ช‡ ๋ถ„ ๋งŒ์—

๋ฌด๋ฃŒ๋กœ ๋งŒ๋“ค๊ธฐ ์‹œ์ž‘ํ•˜๊ธฐ

๋ฌด๋ฃŒ๋กœ ์‹œ์ž‘ ยท ์‹ ์šฉ์นด๋“œ ํ•„์š” ์—†์Œ ยท ์—ฐ๊ตฌ์ž๋ฅผ ์œ„ํ•œ ๋„๊ตฌ

ํ…์ŠคํŠธ๋กœ ๋„ํ˜• ๋งŒ๋“ค๊ธฐ์Šค์ผ€์น˜๋กœ ๋„ํ˜• ๋งŒ๋“ค๊ธฐ์ฐธ์กฐ ์ด๋ฏธ์ง€๋กœ ๋„ํ˜• ๋งŒ๋“ค๊ธฐPDF๋กœ ๋„ํ˜• ๋งŒ๋“ค๊ธฐ์‚ฌ์ง„์œผ๋กœ ๋„ํ˜• ๋งŒ๋“ค๊ธฐ6๊ฐ€์ง€ ์ถœํŒ ์Šคํƒ€์ผํ…์ŠคํŠธ๋กœ ๋„ํ˜• ๋งŒ๋“ค๊ธฐ์Šค์ผ€์น˜๋กœ ๋„ํ˜• ๋งŒ๋“ค๊ธฐ์ฐธ์กฐ ์ด๋ฏธ์ง€๋กœ ๋„ํ˜• ๋งŒ๋“ค๊ธฐPDF๋กœ ๋„ํ˜• ๋งŒ๋“ค๊ธฐ์‚ฌ์ง„์œผ๋กœ ๋„ํ˜• ๋งŒ๋“ค๊ธฐ6๊ฐ€์ง€ ์ถœํŒ ์Šคํƒ€์ผํ…์ŠคํŠธ๋กœ ๋„ํ˜• ๋งŒ๋“ค๊ธฐ์Šค์ผ€์น˜๋กœ ๋„ํ˜• ๋งŒ๋“ค๊ธฐ์ฐธ์กฐ ์ด๋ฏธ์ง€๋กœ ๋„ํ˜• ๋งŒ๋“ค๊ธฐPDF๋กœ ๋„ํ˜• ๋งŒ๋“ค๊ธฐ์‚ฌ์ง„์œผ๋กœ ๋„ํ˜• ๋งŒ๋“ค๊ธฐ6๊ฐ€์ง€ ์ถœํŒ ์Šคํƒ€์ผ
๋ชจ๋“  ํ…์ŠคํŠธ ํŽธ์ง‘ ๊ฐ€๋Šฅ์ •๋ฐ€ ์ธํŽ˜์ธํŠธ๋ฉ€ํ‹ฐ๋ชจ๋‹ฌ ํ–ฅ์ƒ8K ์—…์Šค์ผ€์ผ๋งํŽธ์ง‘ ๊ฐ€๋Šฅํ•œ PPTX๋ ˆ์ด์–ด๋“œ SVG8K PNG / JPG๋ชจ๋“  ํ…์ŠคํŠธ ํŽธ์ง‘ ๊ฐ€๋Šฅ์ •๋ฐ€ ์ธํŽ˜์ธํŠธ๋ฉ€ํ‹ฐ๋ชจ๋‹ฌ ํ–ฅ์ƒ8K ์—…์Šค์ผ€์ผ๋งํŽธ์ง‘ ๊ฐ€๋Šฅํ•œ PPTX๋ ˆ์ด์–ด๋“œ SVG8K PNG / JPG๋ชจ๋“  ํ…์ŠคํŠธ ํŽธ์ง‘ ๊ฐ€๋Šฅ์ •๋ฐ€ ์ธํŽ˜์ธํŠธ๋ฉ€ํ‹ฐ๋ชจ๋‹ฌ ํ–ฅ์ƒ8K ์—…์Šค์ผ€์ผ๋งํŽธ์ง‘ ๊ฐ€๋Šฅํ•œ PPTX๋ ˆ์ด์–ด๋“œ SVG8K PNG / JPG
SciFig

SciFig๋Š” ์—ฐ๊ตฌ์ž๊ฐ€ ์•„์ด๋””์–ด๋ฅผ ์ถœํŒ ๊ฐ€๋Šฅํ•œ ๊ณผํ•™ ๋„ํ˜•์œผ๋กœ ๋ฐ”๊พธ๋„๋ก AI๋กœ ์ง€์›ํ•ฉ๋‹ˆ๋‹ค โ€” ์ €๋„๊ณผ ๋ฐœํ‘œ์šฉ์œผ๋กœ ํŽธ์ง‘ ๊ฐ€๋Šฅํ•œ PPTX, SVG, PNG, JPG๋กœ ๋‚ด๋ณด๋‚ผ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

๋„๊ตฌ

  • ํ…์ŠคํŠธ์—์„œ ๊ทธ๋ฆผ
  • ์Šค์ผ€์น˜์—์„œ ๊ทธ๋ฆผ
  • PDF์—์„œ ๊ทธ๋ฆผ
  • ์ฐธ์กฐ์—์„œ ๊ทธ๋ฆผ
  • ์‚ฌ์ง„์—์„œ ๊ทธ๋ฆผ
  • ๋„ํ˜• ํ–ฅ์ƒ๊ธฐ
  • Vector Canvas

๋ชจ๋ธ

  • GPT Image 2
  • Nano Banana Pro
  • Nano Banana 2

๋ฆฌ์†Œ์Šค

  • ์˜๊ฐ
  • ์‚ฌ์šฉ ๊ฐ€์ด๋“œ
  • ๋ธ”๋กœ๊ทธ

ํšŒ์‚ฌ

  • ์š”๊ธˆ์ œ
  • ์—ฐ๋ฝ์ฒ˜

๋ฒ•์  ๊ณ ์ง€

  • ๊ฐœ์ธ์ •๋ณด ๋ณดํ˜ธ์ •์ฑ…
  • ์„œ๋น„์Šค ์•ฝ๊ด€
  • ์ฟ ํ‚ค ์ •์ฑ…

ยฉ 2026 SciFig. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ .